Febrile non-hemolytic transfusion reaction


Febrile non-hemolytic transfusion reaction is a type of transfusion reaction that is associated with fever but not directly with hemolysis. It is most commonly caused by antibodies directed against donor leukocytes and HLA antigens. More common in multi-transfused patients This is in contrast to transfusion-associated acute lung injury, in which the donor plasma has antibodies directed against the recipient HLA antigens, mediating the characteristic lung damage. Alternatively, FNHTR can be mediated by pre-formed cytokines in the donor plasma as a consequence of white blood cell breakdown. These inflammatory mediators accumulate during the storage of the donated blood, and so the frequency of this reaction increases with the storage length of donated blood.

Definition

Symptoms must manifest within 4 hours of cessation of the transfusion, and should not be due to another cause such as an underlying infection, bacterial contamination of the blood component, or another type of transfusion reaction e.g. acute hemolytic transfusion reaction.
Fever must be at least 38oC/100.4oF oral and a change of at least 1oC/1.8oF from pre-transfusion value OR chills and/or rigors must be present.
The UK hemovigilance system categorizes the severity of the reaction.

Mild

Fever of at least 38oC/100.4oF oral and a change of between 1 and 2oC from pre-transfusion values but no other symptoms or signs

Moderate

Fever of at least 39oC, OR a rise in temperature of at least 2oC from pre-transfusion values AND/OR other symptoms or signs, including chills, painful muscles, or nausea that are severe enough that the transfusion is stopped

Severe

Fever of at least 39oC, OR a rise in temperature of at least 2oC from pre-transfusion values AND/OR other symptoms or signs, including chills, painful muscles, or nausea that are severe enough that the transfusion is stopped AND requires immediate medical treatment, admission to hospital, or lengthens the duration of hospital admission

Treatment

has been used in treatment, and leukoreduction of future transfusions is sometimes performed.